Umer Raffat
Stock Analyst at Evercore ISI Group
(1.37)
# 3,439
Out of 4,944 analysts
21
Total ratings
55.56%
Success rate
-8.5%
Average return
Main Sectors:
Stocks Rated by Umer Raffat
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MTSR Metsera | Initiates: Outperform | n/a | $30.87 | - | 1 | Feb 25, 2025 | |
| SYRE Spyre Therapeutics | Initiates: Outperform | n/a | $17.40 | - | 1 | Jul 16, 2024 | |
| AMLX Amylyx Pharmaceuticals | Downgrades: In-Line | n/a | $8.30 | - | 2 | Mar 8, 2024 | |
| GUTS Fractyl Health | Initiates: Outperform | n/a | $1.01 | - | 1 | Feb 28, 2024 | |
| RAPT RAPT Therapeutics | Initiates: Outperform | n/a | $10.70 | - | 1 | Feb 16, 2024 | |
| ALKS Alkermes | Upgrades: Outperform | n/a | $28.64 | - | 1 | Oct 24, 2023 | |
| CNTA Centessa Pharmaceuticals | Initiates: Outperform | n/a | $17.14 | - | 1 | Jun 21, 2023 | |
| TEVA Teva Pharmaceutical Industries | Upgrades: Outperform | n/a | $17.21 | - | 1 | May 18, 2023 | |
| PHAT Phathom Pharmaceuticals | Upgrades: Outperform | n/a | $10.48 | - | 3 | May 11, 2023 | |
| MLYS Mineralys Therapeutics | Initiates: Outperform | n/a | $13.56 | - | 1 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $36.95 | - | 1 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $9.36 | - | 1 | Jun 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $8.70 | - | 1 | Mar 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $48 | $2.02 | +2,276.24% | 1 | Mar 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $289.33 | - | 2 | Jan 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $48 | $7.28 | +559.34% | 1 | Jun 30, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $117.10 | - | 1 | Feb 23, 2017 |
Metsera
Feb 25, 2025
Initiates: Outperform
Price Target: n/a
Current: $30.87
Upside: -
Spyre Therapeutics
Jul 16, 2024
Initiates: Outperform
Price Target: n/a
Current: $17.40
Upside: -
Amylyx Pharmaceuticals
Mar 8, 2024
Downgrades: In-Line
Price Target: n/a
Current: $8.30
Upside: -
Fractyl Health
Feb 28, 2024
Initiates: Outperform
Price Target: n/a
Current: $1.01
Upside: -
RAPT Therapeutics
Feb 16, 2024
Initiates: Outperform
Price Target: n/a
Current: $10.70
Upside: -
Alkermes
Oct 24, 2023
Upgrades: Outperform
Price Target: n/a
Current: $28.64
Upside: -
Centessa Pharmaceuticals
Jun 21, 2023
Initiates: Outperform
Price Target: n/a
Current: $17.14
Upside: -
Teva Pharmaceutical Industries
May 18, 2023
Upgrades: Outperform
Price Target: n/a
Current: $17.21
Upside: -
Phathom Pharmaceuticals
May 11, 2023
Upgrades: Outperform
Price Target: n/a
Current: $10.48
Upside: -
Mineralys Therapeutics
Mar 7, 2023
Initiates: Outperform
Price Target: n/a
Current: $13.56
Upside: -
Nov 2, 2022
Initiates: Outperform
Price Target: n/a
Current: $36.95
Upside: -
Jun 10, 2021
Initiates: Outperform
Price Target: n/a
Current: $9.36
Upside: -
Mar 12, 2021
Initiates: Outperform
Price Target: n/a
Current: $8.70
Upside: -
Mar 3, 2021
Initiates: Outperform
Price Target: $48
Current: $2.02
Upside: +2,276.24%
Jan 21, 2020
Upgrades: Outperform
Price Target: n/a
Current: $289.33
Upside: -
Jun 30, 2017
Initiates: Outperform
Price Target: $48
Current: $7.28
Upside: +559.34%
Feb 23, 2017
Initiates: Buy
Price Target: n/a
Current: $117.10
Upside: -